Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dinaciclib in Relapsed/Refractory AML and ALL
NCT00798213Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Jan 2009
- Primary completion
- Apr 2010
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of dinaciclib in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), sponsored by Merck & Co.. Started Jan 2009; status: terminated.
02
Drugs
dinaciclib
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00798213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00798213.